Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases

Dicerna CEO tells Scrip the companies talked for two years and the collaboration came together as new Lilly R&D leadership looked to add novel approaches. Milestone fees of $350m per target for 10 or more targets value the deal at $3.7bn.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Dicerna Pharmaceuticals Inc. went on the hunt for partners after refocusing its research and development efforts on its GalXC platform and soon began talking with Eli Lilly & Co. about harnessing the RNAi technology in the big pharma's areas of expertise. Now, the companies have entered into a formal collaboration agreement worth $200m up front and $3.5bn or more in milestone fees.

Cambridge, Mass.-based Dicerna and Lilly announced on Oct. 29 that they will use the GalXC platform to discover, develop and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.